{"podcast":{"title":"Business Of Biotech","slug":"business-of-biotech-123501","podcast_index_feed_id":123501,"rss_url":"https://rss.buzzsprout.com/1011661.rss","website_url":"https://www.bioprocessonline.com/solution/the-business-of-biotech-podcast","image_url":"https://storage.buzzsprout.com/35u0bccu9j9xpr9zrrjias54otax?.jpg","author":"Ben Comer","episode_count":310,"summary":"The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.","last_synced_at":"2026-06-08T22:18:30.179389+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501"},"episode":{"title":"Implementing A New CEO Strategy With NervGen's Adam Rogers, M.D. And Rich Macary","slug":"implementing-a-new-ceo-strategy-with-nervgen-s-adam-rogers-m-d-and-rich-macary","published_at":"2026-04-27T10:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/implementing-a-new-ceo-strategy-with-nervgen-s-adam-rogers-m-d-and-rich-macary","show_page_url":"https://stenobird.com/podcast/business-of-biotech-123501","url":"https://www.buzzsprout.com/1011661/episodes/19058777-implementing-a-new-ceo-strategy-with-nervgen-s-adam-rogers-m-d-and-rich-macary.mp3","audio_url":"https://www.buzzsprout.com/1011661/episodes/19058777-implementing-a-new-ceo-strategy-with-nervgen-s-adam-rogers-m-d-and-rich-macary.mp3","summary":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we talk with NervGen leaders Adam Rogers, M.D., and Rich Macary about NVG-291, a daily neuroreparative peptide designed to restore function in patients with spinal cord injuries. Adam talks about his strategy for the company after becoming CEO last July, including moving company trading from Canada's TSX Venture Exchange to the NASDAQ for better visibility, and making key hires for growt...","meta_description":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we talk with NervGen leaders Adam Rogers, M.D.,…","key_points":[],"chapters":[],"topics":[],"duration_seconds":2857,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/implementing-a-new-ceo-strategy-with-nervgen-s-adam-rogers-m-d-and-rich-macary/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/implementing-a-new-ceo-strategy-with-nervgen-s-adam-rogers-m-d-and-rich-macary.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}